Find and Pitch Jounalists, Get Your Story Covered

Tags: biotech leadership pharma Research & Development research-development

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: U.K. lawmaker wants regulators to probe pharma companies over ‘misleading’ Covid-19 vaccines statements - 9 days ago STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - 3 months ago STAT+: Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more - 4 months ago STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more - 5 months ago STAT+: Pharmalittle: We’re reading about AstraZeneca threatening the U.K., mpox vaccine distribution, and more - 6 months ago STAT+: U.K. trade group scolds Novo, Novartis, Pfizer, and Otsuka for violating industry codes - 8 months ago STAT+: Pharmalittle: We’re reading about AstraZeneca CEO pay, alternatives to WuXi and more - 11 months ago STAT+: European Parliament votes in favor of updated pharma legislation, prompting mixed reactions - 11 months ago STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more - 11 months ago STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more - 11 months ago STAT+: Pharmalittle: We’re reading about Europe’s pharma reform, weight-loss meds, and more - 11 months ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - 12 months ago STAT+: Pharmalittle: We’re reading about a failed schizophrenia drug trial, a Pfizer cancer drug, and more - 12 months ago STAT+: Pharmalittle: We’re reading about weight loss drugs, a cell therapy for melanoma, and more - about 1 year ago STAT+: Major generic maker Aurobindo cuts production at a key plant amid concerns over shortages - about 1 year ago STAT+: European regulators tout their accomplishments against pharma’s anticompetitive practices - about 1 year ago STAT+: Pharmalittle: We’re reading about drug price hikes, Bayer strategic moves, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about FDA’s syphillis-drug plan, India’s manufacturer-inspection demands, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - about 1 year ago STAT+: Pharmalittle: Drugmakers raise prices, pharmacies fear fees, McKinsey settles - about 1 year ago STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud - about 1 year ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - about 1 year ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - about 1 year ago STAT+: Pharmalittle: U.K. approves world’s first CRISPR-based medicine; FDA to review pricey cancer drug lacking confirmatory data - over 1 year ago STAT+: Pharmalittle: German regulator eyes Ozempic export ban amid shortages; NIH-funded clinical trials lagging pharma’s in enrollment - over 1 year ago STAT+: Pharmalittle: Novo Nordisk to spend $6 billion to boost production; FDA okays world’s first vaccine for chikungunya - over 1 year ago STAT+: Pharmalittle: Vertex and U.K. at odds over value of CF meds; French authorities probe Sanofi over alleged market manipulation - over 1 year ago STAT+: Vertex may face another battle in the U.K. over the value of its cystic fibrosis medicines - over 1 year ago STAT+: Pharmalittle: Pharma trade group slams European Commission proposal; U.S. lawmakers demand FDA explain its approach to shortages - over 1 year ago STAT+: Pharmalittle: U.S. Senate eyes more policies for regulating PBMs; Novo claims most U.S. Wegovy patients pay less than $25 a month - over 1 year ago STAT+: Pharmalittle: Novo Nordisk sees “significantly” more Wegovy in the U.S. next year; U.S. pharma layoffs skyrocket - over 1 year ago STAT+: Pharmalittle: Panel tells FDA that CRISPR sickle cell therapy is safe enough for patients; U.K. is urged to scrap IP demands in trade talks with India - over 1 year ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - over 1 year ago STAT+: ‘Missed opportunities’: Why a U.K. government plan to disclose financial ties between pharma and docs may fall short - over 1 year ago STAT+: Pharmalittle: Roche buys Roivant bowel disease drug for $7.1 billion; AstraZeneca CEO calls report of imminent retirement ‘fake news’ - over 1 year ago STAT+: Pharmalittle: Weight-loss drugs fuel boom for firms that fill syringes; employers that cover obesity drug may double in 2024 - over 1 year ago STAT+: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages - over 1 year ago STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties - over 1 year ago
2	Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile educationpolitics	With uncertainty roiling Big Pharma, execs are placing lower-risk bets - 17 days ago By the numbers: J&J, GSK lead J.P. Morgan deal announcements in 2025, the largest turnout in years - about 1 month ago Will 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A? - about 1 month ago Big Pharma earnings hang hope on the next generation of blockbusters - 4 months ago Top pharma and biotech conferences 2025 - 5 months ago Market share shakeup: Big Pharma’s bestselling drugs drive industry shifts in 2024’s first half - 7 months ago Has pharma emerged from the ‘age of uncertainty’? - 7 months ago The thorniest questions facing pharma, according to a leading bioethicist - over 1 year ago
3	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Pharma’s forecast for 2025: Sowing seeds of a rebound - 23 days ago Musk’s rare disease torpedo, hospitals’ pharma fix and other policies leaders are tracking - about 1 month ago The ability to pivot will be ‘key’ as pharma’s tariff threat looms - about 1 month ago 3 closely watched drugs that failed in the clinic - 2 months ago Pharma takes aim at a wily foe — the Epstein-Barr virus - 4 months ago Where competition is heating up in pharma - 9 months ago The biggest questions hanging over pharma in 2024 - about 1 year ago PharmaVoice 100s: Entrepreneurs - over 1 year ago
4	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Boids zone - 3 months ago
5	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 4 months ago
6	Sarah Owermohle STAT News Health reporter @STATNews. Covers Biden's agenda. Washington, District of Columbia health policyjournalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 4 months ago
7	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 4 months ago
8	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	The biotech news roundup to start your week - 4 months ago Serum Institute of India wants government HPV contract - 12 months ago
9	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: U.K. charities give $36 million to start new drugs for childhood tumors - 6 months ago
10	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Pharmalittle: We’re reading about a negative U.K. review of Leqembi, Bavarian Nordic’s strong earnings, and more - 6 months ago

Journalists covering UK pharma